| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5686570 | MSD SUB MERCK | Platelet aggregation inhibitors |
Nov, 2014
(9 years ago) | |
| US5756451 | MSD SUB MERCK | Platelet aggregation inhibitors |
Nov, 2014
(9 years ago) | |
| US5747447 | MSD SUB MERCK | Stable polypeptide composition |
May, 2015
(9 years ago) | |
| US5968902 | MSD SUB MERCK | Platelet aggregation inhibitors |
Jun, 2015
(8 years ago) | |
| US5807825 | MSD SUB MERCK | Platelet aggregation inhibitors |
Sep, 2015
(8 years ago) | |
Integrilin is owned by Msd Sub Merck.
Integrilin contains Eptifibatide.
Integrilin has a total of 5 drug patents out of which 5 drug patents have expired.
Expired drug patents of Integrilin are:
- US5686570
- US5756451
- US5747447
- US5968902
- US5807825
Integrilin was authorised for market use on 18 May, 1998.
Integrilin is available in injectable;injection dosage forms.
Integrilin can be used as platelet aggregation inhibitors, treatment of platelet associated ischemic disorders.
The generics of Integrilin are possible to be released after 15 September, 2015.
Drugs and Companies using EPTIFIBATIDE ingredient
Market Authorisation Date: 18 May, 1998
Treatment: Treatment of platelet associated ischemic disorders; Platelet aggregation inhibitors
Dosage: INJECTABLE;INJECTION
INTEGRILIN family patents
